The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use ...
The European Medicines Agency has recommended the use of Pfizer's gene therapy for a rare bleeding disorder called hemophilia ...
Pfizer (PFE) stock gains as lung cancer therapy, Lorbrena, shows promising results in reducing disease progression or death ...
Pfizer Inc. (NYSE:PFE) is a multinational biotechnology and pharmaceutical company, based in Manhattan, New York City. Recently, Pfizer Inc. (NYSE:PFE) achieved its first US FDA approval for a ...
Gene therapy is a new medical breakthrough which has, in reality, been several decades in the making. The concept was first suggested 50 years ago as a possibility for targeted treatments, but it ...
Five children who were born completely deaf have had some reversal of hearing loss after receiving a "groundbreaking" gene therapy. The clinical trial, which was co-led by Mass Eye and Ear in ...
NEW YORK, May 31 (UPI) --Researchers are engineering ways to alter genes or swap flawed ones with healthy replacements, hoping to cure diseases or enable the body to better combat them. These ...
Welcome to 2024's regulatory tracker for Fierce Pharma. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications.
Stimulants are typically the go-to option for doctors prescribing treatments for attention-deficit hyperactivity disorder (ADHD). But some ADHD patients do not respond adequately to stimulants or ...
The global cell and gene therapy market is experiencing significant growth, driven by technological advancements, increasing ...
Apple’s first big salvo in the AI wars makes a bet that people will care about data privacy when automating tasks. The creative new approach could lead to more energy-efficient machine-learning ...
Five children who were born completely deaf have had some reversal of hearing loss after receiving a "groundbreaking" gene therapy. The clinical trial, which was co-led by Mass Eye and Ear in ...